MCID: IRR002
MIFTS: 57

Irritable Bowel Syndrome

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 41 42 14 69
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9778
ICD10 33 K58 K58.9 K58.0
ICD9CM 35 564.1
MeSH 42 D043183
NCIt 47 C82343
UMLS 69 C0022104

Summaries for Irritable Bowel Syndrome

MedlinePlus : 41 irritable bowel syndrome (ibs) is a problem that affects the large intestine. it can cause abdominal cramping, bloating, and a change in bowel habits. some people with the disorder have constipation. some have diarrhea. others go back and forth between the two. although ibs can cause a great deal of discomfort, it does not harm the intestines. ibs is common. it affects about twice as many women as men and is most often found in people younger than 45 years. no one knows the exact cause of ibs. there is no specific test for it. your doctor may run tests to be sure you don't have other diseases. these tests may include stool sampling tests, blood tests, and x-rays. your doctor may also do a test called a sigmoidoscopy or colonoscopy. most people diagnosed with ibs can control their symptoms with diet, stress management, probiotics, and medicine. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to dyspepsia and asthma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Irritable Bowel Syndrome is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Inflammatory bowel disease (IBD) and Peptide ligand-binding receptors. The drugs Pentoxifylline and Ramosetron have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain, and related phenotypes are Decreased viability and behavior/neurological

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

Disease Ontology : 12 A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

Wikipedia : 72 Irritable bowel syndrome (IBS) is a group of symptoms—including abdominal pain and changes in the... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
id Related Disease Score Top Affiliating Genes
1 dyspepsia 30.4 CCK TAC1
2 asthma 27.7 IL10 TAC1 TLR9 TNF TRPV1
3 isobutyryl-coa dehydrogenase deficiency 11.6
4 gastrointestinal defects and immunodeficiency syndrome 11.4
5 diarrhea 11.3
6 fecal incontinence 11.2
7 interstitial cystitis 11.1
8 pure autonomic failure 10.9 IL10 TNF
9 acute ackee fruit intoxication 10.8 IL10 TNF
10 colonic disease 10.8
11 acquired fructose intolerance 10.8
12 hereditary alpha tryptasemia syndrome 10.8
13 ornithosis 10.7 CCK HTR3A SLC6A4
14 pauci-immune glomerulonephritis with anca 10.7 HTR3A SLC6A4 TNF
15 multiple familial trichoepithelioma 10.7 IL10 TNF
16 nutritional optic neuropathy 10.7 HTR4 MLN
17 basidiobolomycosis 10.6 IL10 TNF
18 lagophthalmos 10.6 IL10 TNF
19 ischemic neuropathy 10.6 CCK HTR3A MLN
20 constipation 10.6
21 type 1 papillary adenoma of the kidney 10.6 IL10 TNF
22 thoracic spinal canal and spinal cord meningioma 10.6 IL10 SLC6A4 TPH1
23 perianal hematoma 10.5 CCK MLN
24 laryngeal adductor paralysis 10.5 CRH SLC6A4 TPH1
25 endosalpingiosis 10.5 IL10 TNF
26 suppurative periapical periodontitis 10.5 SLC6A4 TPH1 TRPV1
27 abnormal pupillary function 10.4 HTR3A HTR7
28 vallecula cancer 10.4 CRH IL10 SLC6A4 TNF
29 perinatal necrotizing enterocolitis 10.4 CCK PYY SLC6A4
30 bile duct cystadenocarcinoma 10.4 CCK MLN PYY
31 hematocele of tunica vaginalis testis 10.4 HTR7 SLC6A4 TNF
32 inflammatory bowel disease 10.4
33 conjunctival pigmentation 10.4 CRH HTR7 SLC6A4
34 colitis 10.4
35 placental insufficiency 10.3 HTR4 HTR7 MLN
36 lynch syndrome 10.3 HTR4 HTR7 MLN
37 carcinoma of unknown primary site, childhood 10.3 CHGA HTR3A PYY
38 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 10.3 CCK PYY TRPV1
39 postencephalitic parkinson disease 10.3 CRHR1 HTR3A SLC6A4 TPH1
40 chagas disease 10.3 CCK HTR3A PYY SLC6A4
41 mucositis 10.3
42 lactose intolerance 10.3
43 inherited metabolic disorder 10.3 PYY TNF TRPV1
44 tularemia 10.2 IL10 TLR9 TNF
45 ostertagiasis 10.2 IL10 TLR9 TNF
46 peroneal nerve paralysis 10.2 IL10 TLR9
47 microscopic colitis 10.2
48 motor peripheral neuropathy 10.2 IL10 TLR9 TNF
49 hypoglycemic coma 10.2 CRH CRHR1 SLC6A4 TPH1
50 sublingual gland cancer 10.2 IL10 TLR9 TNF

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 25)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety Disorder
Atrophic Gastritis Bronchitis
Chronic Myocardial Ischemia Deficiency Anemia
Dependent Personality Disorder Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Generalized Anxiety Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Mitral Valve Disease Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:



Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, vomiting following gastrointestinal surgery, gastrointestinal gas

GenomeRNAi Phenotypes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR3A MLN SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR3A MLN SLC6A4

MGI Mouse Phenotypes related to Irritable Bowel Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 CCK CRH CRHR1 HTR3A HTR4 HTR7
2 homeostasis/metabolism MP:0005376 10.2 CRHR1 HTR3A HTR4 HTR7 IL10 PYY
3 growth/size/body region MP:0005378 10.11 CHGA CRH HTR3A HTR4 IL10 PYY
4 cardiovascular system MP:0005385 10.09 CHGA CRHR1 IL10 SLC6A4 TAC1 TGM2
5 endocrine/exocrine gland MP:0005379 10.06 CCK CHGA CRH CRHR1 HTR3A IL10
6 nervous system MP:0003631 9.97 CCK CRH CRHR1 GNB3 HTR3A HTR4
7 adipose tissue MP:0005375 9.95 CRH HTR4 PYY TNF TPH1 TRPV1
8 integument MP:0010771 9.91 TPH1 TRPV1 CRH HTR3A HTR7 IL10
9 no phenotypic analysis MP:0003012 9.5 CCK CRH CRHR1 IL10 TGM2 TNF
10 renal/urinary system MP:0005367 9.17 TGM2 TLR9 TRPV1 CHGA CRH HTR3A

Drugs & Therapeutics for Irritable Bowel Syndrome

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2 Ramosetron Approved Phase 4,Phase 3,Phase 2 132036-88-5
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
4
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
5
Loperamide Approved Phase 4,Phase 3,Phase 2 53179-11-6 3955
6
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Norepinephrine Approved Phase 4 51-41-2 439260
9
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
10
Alverine Approved Phase 4 150-59-4 3678
11
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
12 Simethicone Approved Phase 4,Phase 1
13
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
14
Pancrelipase Approved Phase 4 53608-75-6
15
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
16
Trimebutine Approved Phase 4 39133-31-8
17
Metronidazole Approved Phase 4 443-48-1 4173
18
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
19
Lubiprostone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136790-76-6 656719
20
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
21
Pantoprazole Approved Phase 4 102625-70-7 4679
22
Eluxadoline Approved Phase 4 864821-90-9
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
24
Amitriptyline Approved Phase 4 50-48-6 2160
25
Perphenazine Approved Phase 4 58-39-9 4748
26
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
27
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 1 67-97-0 6221 10883523 5280795
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 1406-16-2
29 Tiropramide Investigational Phase 4 55837-29-1 42262
30 Mosapride Investigational Phase 4,Phase 3,Phase 2 112885-41-3
31
Curcumin Investigational Phase 4,Phase 2 458-37-7 969516
32
Mebeverine Investigational Phase 4 3625-06-7 62887
33 Ebastine Investigational Phase 4 90729-43-4
34 Fenoverine Investigational Phase 4 37561-27-6
35
Maleic acid Experimental Phase 4 110-16-7 444266
36
Genistein Investigational Phase 4 446-72-0 5280961
37
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
38 Anticonvulsants Phase 4,Phase 2
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Bromides Phase 4
41 calcium channel blockers Phase 4,Phase 2
42 Calcium, Dietary Phase 4,Phase 3,Phase 2
43 Cholinergic Agents Phase 4,Phase 2
44 Cholinergic Antagonists Phase 4,Phase 2
45 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Muscarinic Antagonists Phase 4,Phase 2
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Octylonium Phase 4
49 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 642)

id Name Status NCT ID Phase Drugs
1 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
2 Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
3 Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
4 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
5 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
6 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
7 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
8 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
9 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
10 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
11 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Unknown status NCT01667627 Phase 4
12 Effect of Ramosetron on Bowel Motility After Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
13 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
14 Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
15 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Completed NCT00401258 Phase 4 duloxetine
16 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
17 Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
18 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
19 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
20 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
21 Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome Completed NCT01331213 Phase 4 Pregabalin;Placebo
22 Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS) Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
23 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
24 A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients Completed NCT01225237 Phase 4 Ramosetron;Placebo
25 A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
26 Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
27 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4 Mesalazine;Placebo
28 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
29 Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study Completed NCT02077699 Phase 4
30 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
31 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
32 Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
33 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Completed NCT02111603 Phase 4 Colesevelam
34 Comparative Efficacy and Safety of Fenoverine Completed NCT01507922 Phase 4 Fenoverine;Timebutine
35 Multi-strain Probiotic in the Management of IBS-D Completed NCT03251625 Phase 4 Probiotic Formula Capsule
36 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
37 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
38 EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
39 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4 Ondansetron;Placebo
40 Study to Assess the Effect Of Alosetron On Mucosal Blood Flow Completed NCT00370032 Phase 4 alosetron
41 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
42 Mode of Action of Moviprep Completed NCT01622972 Phase 4 Polyethyleneglycol
43 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
44 Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption Completed NCT01763281 Phase 4 CRH;Placebo
45 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
46 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
47 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
48 Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children Completed NCT01595932 Phase 4
49 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Recruiting NCT02614963 Phase 4 Clostridium Butyricum;placebo
50 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Recruiting NCT02728063 Phase 4

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

39
Colon, Testes, Brain, Small Intestine, Kidney, Liver, Heart

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 985)
id Title Authors Year
1
The Place of Stress and Emotions in the Irritable Bowel Syndrome. ( 28061975 )
2017
2
Intestinal microbiome-gut-brain axis and irritable bowel syndrome. ( 28887729 )
2017
3
Structural and functional alterations in the colonic microbiome of the rat in a model of stress induced irritable bowel syndrome. ( 28059627 )
2017
4
Irritable Bowel Syndrome-Like Symptoms Following Fecal Microbiota Transplantation: A Possible Donor-Dependent Complication. ( 28050036 )
2017
5
Chronic Urticaria and Irritable Bowel Syndrome: a Cross-Sectional Study of 11,271 Patients. ( 28906546 )
2017
6
Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test? ( 28074509 )
2017
7
Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders. ( 28951738 )
2017
8
Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. ( 28886490 )
2017
9
Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners. ( 28092305 )
2017
10
Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. ( 28894393 )
2017
11
Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. ( 28936910 )
2017
12
Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. ( 27862119 )
2017
13
Antinociceptive Effect of Ghrelin in a Rat Model of Irritable Bowel Syndrome Involves TRPV1/Opioid Systems. ( 28930716 )
2017
14
Effect of retrograde colonic electrical stimulation on colonic transit and stress-induced visceral hypersensitivity in rats with irritable bowel syndrome. ( 28942833 )
2017
15
Postinfection Irritable Bowel Syndrome: The Links Between Gastroenteritis, Inflammation, the Microbiome, and Functional Disease. ( 28885302 )
2017
16
Microscopic colitis: a missed diagnosis among patients with moderate to severe irritable bowel syndrome. ( 27796144 )
2017
17
Childhood bladder and bowel dysfunction predicts irritable bowel syndrome phenotype in adult interstitial cystitis/bladder pain syndrome patients. ( 28798827 )
2017
18
COMT Val158Met Polymorphism and Symptom Improvement Following a Cognitively Focused Intervention for Irritable Bowel Syndrome. ( 28252569 )
2017
19
The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. ( 28932272 )
2017
20
Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. ( 28932269 )
2017
21
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. ( 28083815 )
2017
22
Increased Expression of Toll-Like Receptors 4, 5, and 9 in Small Bowel Mucosa from Patients with Irritable Bowel Syndrome. ( 28246611 )
2017
23
Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome. ( 28054654 )
2017
24
Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: a Systematic Review and Meta-analysis. ( 28069350 )
2017
25
Post-Infectious Irritable Bowel Syndrome. ( 28948467 )
2017
26
Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. ( 27869798 )
2017
27
Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology and management. ( 28901578 )
2017
28
Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply. ( 28880440 )
2017
29
The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals. ( 27750262 )
2017
30
Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? ( 28880445 )
2017
31
Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. ( 28680646 )
2017
32
Is-it possible to distinguish irritable bowel syndrome with constipation from functional constipation? ( 28066860 )
2017
33
Blastocystis and irritable bowel syndrome: Frequency and subtypes from Iranian patients. ( 28087441 )
2017
34
Giardiasis and Subsequent Irritable Bowel Syndrome: A Longitudinal Cohort Study Using Health Insurance Data. ( 28329069 )
2017
35
Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. ( 28160607 )
2017
36
Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. Authors' reply. ( 28074518 )
2017
37
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. ( 28932270 )
2017
38
Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome. ( 28884838 )
2017
39
Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome. ( 28937377 )
2017
40
Self-rated health and functional capacity in individuals reporting overlapping symptoms of gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome - a population based study. ( 28521729 )
2017
41
Comparison of Resilience and Psychological Wellbeing in Women with Irritable Bowel Syndrome and Normal Women. ( 28883772 )
2017
42
Damage of the Mucus Layer: The Possible Shared Critical Common Cause for Both Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). ( 28079624 )
2017
43
Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. ( 28074514 )
2017
44
The Severity of Symptoms Related to Irritable Bowel Syndrome is a Risk Factor for the Misclassification of Significant Organic Disease. ( 27661976 )
2016
45
Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial. ( 27154424 )
2016
46
Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome? ( 27634230 )
2016
47
Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. ( 27157575 )
2016
48
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. ( 27644732 )
2016
49
The prevalence of celiac disease in patients with irritable bowel syndrome and its subtypes. ( 28053683 )
2016
50
Patterns of alternation in irritable bowel syndrome. ( 27152072 )
2016

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

Pathways related to Irritable Bowel Syndrome according to KEGG:

37
id Name Kegg Source Accession
1 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 CCK CRH CRHR1 GNB3 HTR4 HTR7
2
Show member pathways
13.12 GNB3 HTR3A HTR3E HTR4 HTR7 TGM2
4 11.91 GNB3 HTR3A IL10 SLC6A4 TAC1 TNF
5 11.82 CRH CRHR1 GNB3 HTR4 HTR7
6
Show member pathways
11.74 IL10 TLR9 TNF
7 11.67 CRH CRHR1 GNB3
8 11.57 IL10 TLR9 TNF
9 11.48 IL10 TLR9 TNF
10 11.27 IL10 TLR9 TNF
11 11.22 GNB3 HTR3A HTR3E HTR4 HTR7 SLC6A4
12 11.09 IL10 TLR9 TNF
13 10.8 HTR3A HTR4 HTR7 SLC6A4 TPH1
14 10.28 CRH CRHR1

GO Terms for Irritable Bowel Syndrome

Cellular components related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 CCK CHGA CRH IL10 MLN PYY
2 extracellular space GO:0005615 9.76 CCK CHGA CRH IL10 PYY TAC1
3 neuronal cell body GO:0043025 9.35 CCK CRH HTR3A TAC1 TRPV1
4 intrinsic component of plasma membrane GO:0031226 8.8 CRHR1 TGM2 TRPV1
5 plasma membrane GO:0005886 10.1 CRHR1 GNB3 HTR3A HTR3E HTR4 HTR7

Biological processes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.81 CRH HTR4 HTR7 TAC1
2 defense response to bacterium GO:0042742 9.8 CHGA IL10 TLR9 TNF
3 response to organic substance GO:0010033 9.75 IL10 SLC6A4 TNF
4 circadian rhythm GO:0007623 9.73 HTR7 SLC6A4 TPH1
5 regulation of blood pressure GO:0008217 9.65 CHGA GNB3 TAC1
6 positive regulation of chemokine production GO:0032722 9.59 TLR9 TNF
7 negative regulation of growth of symbiont in host GO:0044130 9.58 IL10 TNF
8 response to molecule of bacterial origin GO:0002237 9.57 IL10 TLR9
9 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.55 IL10 TNF
10 parturition GO:0007567 9.54 CRH CRHR1
11 regulation of appetite GO:0032098 9.52 HTR4 PYY
12 endothelial cell apoptotic process GO:0072577 9.46 IL10 TNF
13 negative regulation of interleukin-6 production GO:0032715 9.43 IL10 TLR9 TNF
14 negative regulation of cytokine secretion involved in immune response GO:0002740 9.4 IL10 TNF
15 negative regulation of interleukin-8 production GO:0032717 9.37 IL10 TLR9
16 receptor biosynthetic process GO:0032800 9.32 IL10 TNF
17 positive regulation of corticosterone secretion GO:2000854 9.16 CRH TAC1
18 response to pain GO:0048265 9.13 CRH TAC1 TRPV1
19 inflammatory response GO:0006954 9.1 CRH IL10 TAC1 TLR9 TNF TRPV1
20 signal transduction GO:0007165 10.03 CCK CRH CRHR1 GNB3 HTR3E HTR4

Molecular functions related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.32 HTR3A HTR7
2 serotonin-gated cation channel activity GO:0022850 9.26 HTR3A HTR3E
3 extracellular ligand-gated ion channel activity GO:0005230 9.16 HTR3A TRPV1
4 neuropeptide hormone activity GO:0005184 9.13 CCK CRH PYY
5 hormone activity GO:0005179 8.92 CCK CRH MLN PYY

Sources for Irritable Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....